龍津藥業(002750.SZ):子公司對外投資取得控股子公司柔以時
格隆匯6月29日丨龍津藥業(002750.SZ)公佈,全資子公司雲南龍津梵天生物科技有限責任公司近日簽署上海柔以時生物科技有限公司《股東會決議》、《公司章程》,並已取得工商行政部門《登記通知書》。龍津梵天將向參股公司上海柔以時生物科技有限公司(簡稱“柔以時”)以現金方式增資3000萬元,其持股比例由增資前的10%增加至75.61%;柔以時原有其他股東放棄本次增資的優先購買權,並引進新股東雲南越見文化傳播有限公司增資100萬元,持股比例為2.44%。本次增資最終繳款時限為2023年12月31日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.